IDH mutations result in down-regulation of genes involved in immune activation of cancer cells likely occurring either by a direct metabolic inhibitory effect of D2-HG or through epigenetic reprogramming by hypermethylation of promotors of immune-related genes (47). Here, IDH1 is linked to cancer.